GGrantIndex
Sort

10,766 grants matching checkpoint inhibitor

Effective combination therapy for MTAP-deficient bladder carcinoma by targeting metabolic vulnerability and modulating tumor immune microenvironment

$535,778
Jianjun Gao · University Of Tx Md Anderson Can Ctr · R01 · FY2025 · CA

Effective combination therapy for MTAP-deficient bladder carcinoma by targeting metabolic vulnerability and modulating tumor immune microenvironment

$535,778
Jianjun Gao · University Of Tx Md Anderson Can Ctr · R01 · FY2022 · CA

Effective combination therapy for MTAP-deficient bladder carcinoma by targeting metabolic vulnerability and modulating tumor immune microenvironment

$535,778
Jianjun Gao · University Of Tx Md Anderson Can Ctr · R01 · FY2021 · CA

Cyclin Dependent Kinases as Epigenetic Therapy Targets

$535,736
Jean-Pierre J Issa · Coriell Institute For Medical Research · P50 · FY2025 · CA

A new mouse model for studying the pathogenesis and immunobiology of intrahepatic cholangiocarcinoma and improving its immunotherapy

$535,708
Michael Karin · University Of California, San Diego · R01 · FY2024 · CA

Potentiating a systemic antitumor response by interstitial localized ablative immunotherapy to synergize with immune checkpoint therapy for metastatic pancreatic tumors

$535,638
Wei R. Chen · University Of Oklahoma · R01 · FY2022 · CA

Escape from CAR T surveillance through lineage plasticity

$535,637
Patricia A Ernst · University Of Colorado Denver · R01 · FY2024 · CA

A novel signaling mechanism for LRP5

$535,605
Dianqing Wu · Yale University · R01 · FY2023 · CA

Regulation of Mitotic Kinetochores by the Ran GTPase

$535,580
Mary C. Dasso · Eunice Kennedy Shriver National Institute Of Child Health & Human Development · ZIA · FY2009 · HD

FEEDBACK CONTROL OF THE CELL CYCLE

$535,579
Andrew W Murray · Harvard University · R37 · FY2009 · GM

STING-Activating Polymeric Nanovaccines for T Cell Therapy of Melanoma

$535,530
Jinming Gao · Ut Southwestern Medical Center · U01 · FY2017 · CA

STING-Activating Polymeric Nanovaccines for T Cell Therapy of Melanoma

$535,530
Jinming Gao · Ut Southwestern Medical Center · U01 · FY2021 · CA

STING-Activating Polymeric Nanovaccines for T Cell Therapy of Melanoma

$535,530
Jinming Gao · Ut Southwestern Medical Center · U01 · FY2018 · CA

In vivo imaging of mitochondria structure and function in therapy resistant lung tumors

$535,514
David B Shackelford · University Of California Los Angeles · R01 · FY2025 · CA

In vivo imaging of mitochondria structure and function in therapy resistant lung tumors

$535,514
David B Shackelford · University Of California Los Angeles · R01 · FY2022 · CA

Targeting HER2-low breast cancer with 17p loss

$535,448
Xiongbin Lu · Indiana University Indianapolis · R01 · FY2021 · CA

Engineered Nanoformulation for Immune-modulation in Cancer

$535,400
Rajagopal Ramesh · University Of Oklahoma Hlth Sciences Ctr · R01 · FY2024 · CA

Targeting Systems Vulnerabilities in the Gαq/GNAQ Oncogenic Signaling Circuitry: New Precision Therapies for Uveal Melanoma

$535,362
J. Silvio Gutkind · University Of California, San Diego · R01 · FY2022 · CA

Project 1: Multi-scale modeling of adaptive drug resistance in BRAF-mutant melanoma

$535,239
Peter Karl Sorger · Harvard Medical School · U54 · FY2022 · CA

Elucidating Mechanism of Immune Evasion in Head and Neck Cancers

$535,210
Jing Hong Wang · University Of Pittsburgh At Pittsburgh · R01 · FY2022 · DE

Systemic RNA Delivery to Tumors

$535,205
Jinjun Shi · Brigham And Women'S Hospital · R01 · FY2022 · CA

Glutaredoxin, Glutathione Metabolism and Lung Cancer

$535,116
Yvonne M.w. Janssen-Heininger · University Of Vermont & St Agric College · R01 · FY2023 · CA

Novel roles of PCSK9 in regulating the tumor immune microenvironment during radiotherapy

$535,077
Yunyan Jennifer Jennifer Zhang · Duke University · R01 · FY2025 · CA

Novel roles of PCSK9 in regulating the tumor immune microenvironment during radiotherapy

$535,077
Chuan-Yuan Li · Duke University · R01 · FY2022 · CA

Targeting the cGAS/STING Pathway to Overcome Resistance to Immune Checkpoint Inhibitors in PTEN-deficient Prostate Cancer

$534,674
Akash Patnaik · University Of Chicago · R01 · FY2022 · CA